ClinicalTrials.gg
CompletedNCT05121714Updated Nov 9, 2026Results posted

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

A Phase 1 interventional study of Caffeine and ABX464 in Healthy, sponsored by Abivax S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Abivax S.A. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2020, registered Oct 2021).
Updated Nov 9, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs

Read the detailed description

This is a Phase 1, 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine) and a known CYP1A2 inhibitor (fluvoxamine). Up to sixty (60) healthy adult male and female subjects 18 to 55 years of age are planned to participate in the study. Separate cohorts of subjects will be enrolled for Part A (up to 24 subjects enrolled to allow 22 subjects required to complete Part A ) and Part B (up to 36 subjects enrolled to allow 32 subjects were to complete Part B).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, male or female subject, between 18 and 55 years of age, inclusive.
  2. Women of (WOCBP) and men receiving the study treatment and their partners must agree to use a highly effective method during the study and for 6 months (180 days) after end of study or early termination.
  3. Subject with a (BMI) of 18.5-30 kilogrammes per square metre (kg/m²).
  4. No history of previous allergy / sensitivity to ABX464 or any of the within the IMP.
  5. No clinically significant history of previous allergy / sensitivity to caffeine (for Part A) or fluvoxamine (for Part B), or any of the excipients contained within the Non- Medicinal Product (NIMP).
  6. No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the Investigational Medicinal Product (IMP)/NIMP.
  7. Subject with a negative urinary drugs of abuse (DOA) screen (including alcohol and cotinine) test results, determined within 28 days before the first dose administration of the IMP (N.B.: A positive result may be repeated at the Investigator's discretion).
  8. Subject with negative (HIV) antibodies, surface antigen (HBsAg)) and virus antibody (HCV Ab) results at Screening.
  9. No known history of hypertension or abnormal vital signs at screening defined as supine systolic blood pressure (SBP) \< 90 or > 140 millimetres of mercury (mmHg), and pulse rate \< 40 or > 90 beats per minute (bpm).
  10. No clinically significant abnormalities in 12-lead (ECG) determined within 28 days before first dose of IMP including PR > 220 milliseconds (ms) and corrected using Fridericia formula (QTcF) >450 ms in males or >470 ms in females, or evidence of clinically significant dysrhythmias (long QT features on ECG, left bundle branch block, or ventricular arrhythmia), atrial fibrillation or history of familial long QT syndromes (Note: partial right bundle branch block is acceptable).
  11. Subject must be available to complete the study (including all follow up visits/phone call).
  12. Subject must satisfy an Investigator about their fitness to participate in the study.
  13. Subject must provide written to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Female subject who is pregnant, currently lactating or breastfeeding.
  2. A history of gastrointestinal disorder likely to influence IMP absorption.
  3. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, or any product known to interact with CYP1A2 within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP.
  4. Subject who has, or who have a relevant history of any clinically significant: neurological, gastrointestinal, renal, hepatic, cardiovascular, vascular, psychiatric, respiratory, metabolic, endocrine, or haematological conditions and/or other significant medical conditions including, without limitation, those pertaining to coronavirus disease 2019 (COVID-19) that, in the opinion of the Investigator or their appropriately qualified designee, would jeopardise the safety of the subject, safety of anyone involved in the study or impact on the validity of the study results.
  5. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units for male and female subjects) of alcohol a week) within the past two years.
  6. Inability to communicate well with the Investigators (i.e., language problem, poor mental development or impaired cerebral function).
  7. Participation in a New Chemical Entity (NCE) clinical study within 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within 30 days or five half-lives, whichever is longer, before the first dose of IMP ( between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  8. Donation of 450 millilitres (mL) or more blood within the 3 months before the first dose of IMP.
  9. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to first dose administration with the study medication or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).
  10. Total serum , alkaline phosphatase (ALP), (AST) / serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT) / Serum glutamic pyruvic transaminase (SGPT) > 1.5 x (ULN).
  11. Experiences regular headaches (i.e., experiences headaches more than weekly).

    Part B Only:

  12. Meets (5th Edition) criteria for moderate or severe substance use disorder within 6 months before Screening.
  13. Reports having experienced suicidal ideation (Type 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]) within 30 days prior to Screening, any suicidal behaviour within 2 years prior to Screening (Any "Yes" answers on Suicidal Behaviour section of C-SSRS), and/or the Investigator assesses the subject to be a safety risk to him/herself or others;
  14. Clinically significant history of depression or anxiety.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Other
    Evaluation of CYP1A2 inhibition and induction potential by ABX464

    Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days). Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.

    Drug: Caffeine · Drug: ABX464

  • Other
    Evaluation of ABX464 as a substrate for CYP1A2

    Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days). ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2

    Drug: ABX464 · Drug: Fluvoxamine

Interventions

  • This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)

  • DrugABX464

    This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).

  • This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).

06

What researchers measure

Primary outcomes

  1. Part A - Day 1 Peak Plasma Concentration of Caffeine

    Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 1

  2. Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464

    Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 4

  3. Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464

    Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 17

  4. Part A - Day 1 AUC of Caffeine

    Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 1

  5. Part A - Day 4 AUC of Caffeine & ABX464

    Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 4

  6. Part A - Day 17 AUC of Caffeine & ABX464

    Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

    Time frame: Day 17

  7. Part B - Day 1 - Peak Plasma Concentration of ABX464

    Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5,5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

    Time frame: Day 1

  8. Part B - Day 11 - Peak Plasma Concentration of ABX464

    Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h.Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

    Time frame: Day 11

  9. Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)

    Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

    Time frame: Day 1

  10. Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)

    Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

    Time frame: Day 11

Secondary outcomes

  1. Number of Adverse Events (AEs)

    Number of Adverse Events (AEs): Parts A \& B safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine

    Time frame: From baseline up to Day 25

07

Results

Posted Nov 9, 2026
Limitations and caveats
N/A - although a number of participants were excluded from the PK analysis sets, this did not impact on the overall evaluation of the study objectives.

Participant flow

Study recruitment for this study was undertaken in South Wales in the United Kingdom. The recruitment process began in December 2020 and concluded in April 2021. 164 subjects were screened in order to successfully recruit 59 eligible participants.

Participant flow — Overall Study
MilestonePart A- Caffeine First, Then ABX64 With and Without Caffeine, Followed by ABX64 With CaffeinePart B-ABX64 First, Then Fluvoxamine, Followed by ABX64 With Fluvoxamine"
Started2435
Completed2434
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPart A - Day 1 Peak Plasma Concentration of Caffeine

Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 1
Reported as:
Mean · ng/mL
Part A - Day 1 Peak Plasma Concentration of Caffeine
ng/mLPart A - PK Analysis Set
Part A - Day 1 Peak Plasma Concentration of Caffeine931 ± 285
PrimaryPart A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464

Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 4
Reported as:
Mean · ng/mL
Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464
ng/mLPart A - PK Analysis Set
Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464930 ± 278
PrimaryPart A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464

Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 17
Reported as:
Mean · ng/mL
Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464
ng/mLPart A - PK Analysis Set
Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464564 ± 242
PrimaryPart A - Day 1 AUC of Caffeine

Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 1
Reported as:
Mean · h*ng/mL
Part A - Day 1 AUC of Caffeine
h*ng/mLPart A - PK Analysis Set
Part A - Day 1 AUC of Caffeine7420 ± 4760
PrimaryPart A - Day 4 AUC of Caffeine & ABX464

Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 4
Reported as:
Mean · h*ng/mL
Part A - Day 4 AUC of Caffeine & ABX464
h*ng/mLPart A - PK Analysis Set
Part A - Day 4 AUC of Caffeine & ABX4645460 ± 2740
PrimaryPart A - Day 17 AUC of Caffeine & ABX464

Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).

Time frame:
Day 17
Reported as:
Mean · h*ng/mL
Part A - Day 17 AUC of Caffeine & ABX464
h*ng/mLPart A - PK Analysis Set
Part A - Day 17 AUC of Caffeine & ABX4641560 ± 719
PrimaryPart B - Day 1 - Peak Plasma Concentration of ABX464

Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5,5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

Time frame:
Day 1
Reported as:
Mean · ng/mL
Part B - Day 1 - Peak Plasma Concentration of ABX464
ng/mLPart B PK Analysis Set
Part B - Day 1 - Peak Plasma Concentration of ABX46423.2 ± 12.5
PrimaryPart B - Day 11 - Peak Plasma Concentration of ABX464

Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h.Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

Time frame:
Day 11
Reported as:
Mean · ng/mL
Part B - Day 11 - Peak Plasma Concentration of ABX464
ng/mLPart B PK Analysis Set
Part B - Day 11 - Peak Plasma Concentration of ABX46433.4 ± 19.0
PrimaryPart B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)

Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

Time frame:
Day 1
Reported as:
Mean · h*ng/mL
Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)
h*ng/mLPart B PK Analysis Set
Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)55.2 ± 25.7
PrimaryPart B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)

Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).

Time frame:
Day 11
Reported as:
Mean · h*ng/mL
Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)
h*ng/mLPart B PK Analysis Set
Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)73.0 ± 34.2
SecondaryNumber of Adverse Events (AEs)

Number of Adverse Events (AEs): Parts A \& B safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine

Time frame:
From baseline up to Day 25
Reported as:
Count of participants · Participants
Number of Adverse Events (AEs)
ParticipantsPart A Participants - Safety Analysis SetPart B Participants - Safety Analysis Set
Number of Adverse Events (AEs)1630

Adverse events

Collected over Adverse events were reported throughout the study from Day -1 until completion of the post study follow up visit (approximately 9 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A- Caffeine Only (Day 1)0/24 (0%)0/24 (0%)2/24 (8.3%)
Part A - Caffeine and ABX464 (Day 4)0/24 (0%)0/24 (0%)10/24 (41.7%)
Part A - ABX464 Only (Days 5-16)0/24 (0%)0/24 (0%)14/24 (58.3%)
Part A - Caffeine and ABX464 (Day 17)0/24 (0%)0/24 (0%)3/24 (12.5%)
Part A Overall0/24 (0%)0/24 (0%)16/24 (66.7%)
Part B - ABX464 Only (Day 1)0/35 (0%)0/35 (0%)23/35 (65.7%)
Part B - Fluvoxamine Only (Days 2-10)0/35 (0%)0/35 (0%)24/35 (68.6%)
Part B - ABX464 and Fluvoxamine (Day 11)0/34 (0%)0/34 (0%)21/34 (61.8%)
Part B - Fluvoxamine Only (Days 12-25)0/34 (0%)0/34 (0%)11/34 (32.4%)
Part B Overall0/35 (0%)0/35 (0%)30/35 (85.7%)
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPart A- Caffeine Only (Day 1)Part A - Caffeine and ABX464 (Day 4)Part A - ABX464 Only (Days 5-16)Part A - Caffeine and ABX464 (Day 17)Part A OverallPart B - ABX464 Only (Day 1)Part B - Fluvoxamine Only (Days 2-10)Part B - ABX464 and Fluvoxamine (Day 11)Part B - Fluvoxamine Only (Days 12-25)Part B Overall
HeadacheNervous system disorders1/248/2413/241/2413/2421/351/3517/343/3425/35
NauseaGastrointestinal disorders0/246/241/241/247/2410/3510/3510/341/3420/35
Decreased AppetiteMetabolism and nutrition disorders0/240/241/240/241/240/3514/351/340/3415/35
FatigueGeneral disorders0/240/243/240/243/240/3513/350/341/3414/35
VomitingGastrointestinal disorders0/242/240/240/242/248/352/356/340/3411/35
InsomniaPsychiatric disorders0/240/240/240/240/241/358/350/341/348/35
LethargyGeneral disorders0/240/243/240/243/240/352/350/340/342/35
DizzinessNervous system disorders0/241/240/241/242/240/353/350/340/343/35
DiarrhoeaGastrointestinal disorders0/240/241/240/241/240/351/350/341/342/35
FlatulenceGastrointestinal disorders0/240/241/240/241/241/351/350/340/342/35

Baseline characteristics

This baseline analysis population corresponds to the number of participants included within the Safety Analysis set population for the study for each respective part.

Age, Categorical
Age, Categorical(Participants)Part A & Part B
Part A — <=18 years0
Part A — Between 18 and 65 years24
Part A — >=65 years0
Part B — <=18 years0
Part B — Between 18 and 65 years35
Part B — >=65 years0
Age, Continuous
Age, Continuous(Years)Part A & Part B
Part A33.7 ± 9.44
Part B36.8 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)Part A & Part B
Part A — Female5
Part A — Male19
Part B — Female13
Part B — Male22
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Part A & Part B
Region of Enrollment
Region of Enrollment(participants)Part A & Part B
United Kingdom59
Screening Weight
Screening Weight(Kilograms)Part A & Part B
Part A78.86 ± 12.473
Part B78.60 ± 15.810
Height
Height(Metres)Part A & Part B
Part A1.758 ± 0.0923
Part B1.738 ± 0.1021
Body Mass Index
Body Mass Index(kg/m^2)Part A & Part B
Part A25.379 ± 2.4786
Part B25.743 ± 2.7545
08

Study locations

1 site
  • Simbec-Orion
    Merthyr Tydfil, CF48 4DR, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in May 2021, 5 months.

Results were first posted in Nov 2026, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Nov 16, 2021
StartActual
Dec 17, 2020
Primary completionActual
May 18, 2021
CompletionActual
May 18, 2021
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Primary outcomes
1 edited, 9 added, 3 removed
What changed in the outcomes
  • EditedPart B Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on- Day 1 - Area underUnder the plasma concentration versus time curvePlasma Concentration Versus Time Curve (AUC) in the presence and absence of fluvoxamine.Time frame: Day 1 and Day 11 → Day 1
  • AddedPart A - Day 1 Peak Plasma Concentration of CaffeineTime frame: Day 1
  • AddedPart A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 4
  • AddedPart A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 17
  • AddedPart A - Day 1 AUC of CaffeineTime frame: Day 1
  • AddedPart A - Day 4 AUC of Caffeine & ABX464Time frame: Day 4
  • AddedPart A - Day 17 AUC of Caffeine & ABX464Time frame: Day 17
  • AddedPart B - Day 1 - Peak Plasma Concentration of ABX464Time frame: Day 1
  • AddedPart B - Day 11 - Peak Plasma Concentration of ABX464Time frame: Day 11
  • AddedPart B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 11
  • RemovedPart A Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the Peak Plasma Concentration (Cmax) of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.Time frame: Day 1, Day 4 and Day 17
  • RemovedPart A Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the Area under the plasma concentration versus time curve (AUC) of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.Time frame: Day 1, Day 4 and Day 17
  • RemovedPart B Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on Peak Plasma Concentration (Cmax) in the presence and absence of fluvoxamine.Time frame: Day 1 and Day11
Nov 9, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Parts A & B • Evaluate the safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamineNow Number of Adverse Events (AEs)Time frame: from baseline up to Day 25 → From baseline up to Day 25
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    Primary outcomes 1 edited, 9 added, 3 removed
    What changed in the outcomes
    • EditedPart B Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on- Day 1 - Area underUnder the plasma concentration versus time curvePlasma Concentration Versus Time Curve (AUC) in the presence and absence of fluvoxamine.Time frame: Day 1 and Day 11 → Day 1
    • AddedPart A - Day 1 Peak Plasma Concentration of CaffeineTime frame: Day 1
    • AddedPart A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 4
    • AddedPart A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 17
    • AddedPart A - Day 1 AUC of CaffeineTime frame: Day 1
    • AddedPart A - Day 4 AUC of Caffeine & ABX464Time frame: Day 4
    • AddedPart A - Day 17 AUC of Caffeine & ABX464Time frame: Day 17
    • AddedPart B - Day 1 - Peak Plasma Concentration of ABX464Time frame: Day 1
    • AddedPart B - Day 11 - Peak Plasma Concentration of ABX464Time frame: Day 11
    • AddedPart B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 11
    • RemovedPart A Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the Peak Plasma Concentration (Cmax) of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.Time frame: Day 1, Day 4 and Day 17
    • RemovedPart A Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the Area under the plasma concentration versus time curve (AUC) of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.Time frame: Day 1, Day 4 and Day 17
    • RemovedPart B Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on Peak Plasma Concentration (Cmax) in the presence and absence of fluvoxamine.Time frame: Day 1 and Day11
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Parts A & B • Evaluate the safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamineNow Number of Adverse Events (AEs)Time frame: from baseline up to Day 25 → From baseline up to Day 25
    + 5 other changes: verification date, description, arm descriptions, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05121714
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Nov 16, 2021
Start date
Dec 17, 2020
Primary completion
May 18, 2021
Completion
May 18, 2021
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

Paul Gineste
study director · Abivax S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ABX464 · Fluvoxamine

Start the discussion